Bone Biologics Corp Warrants closed at $4.06 on Sep 18, down 5.58%, 88.7% below its highest close since Oct 13. Volume of 635 shares was 0.40× its 20-day average (below normal).
Split-adjusted performance: -46.9% over one month.
Short interest was 150 shares at the Sep 15 settlement, down 58.6% from the prior report (1.0 days to cover).
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration.
What sector is BBLGW in?
Healthcare, in the Orthopedic & Surgical Supplies industry.
About Bone Biologics Corp Warrants
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology